Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346).

Tangen CM, Hussain MH, Higano CS, Eisenberger MA, Small EJ, Wilding G, Donnelly BJ, Schelhammer PF, Crawford ED, Vogelzang NJ, Powell IJ, Thompson IM Jr.

J Urol. 2012 Oct;188(4):1164-9. doi: 10.1016/j.juro.2012.06.046. Epub 2012 Aug 22.

2.

Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).

James ND, Spears MR, Clarke NW, Dearnaley DP, De Bono JS, Gale J, Hetherington J, Hoskin PJ, Jones RJ, Laing R, Lester JF, McLaren D, Parker CC, Parmar MK, Ritchie AW, Russell JM, Strebel RT, Thalmann GN, Mason MD, Sydes MR.

Eur Urol. 2015 Jun;67(6):1028-38. doi: 10.1016/j.eururo.2014.09.032. Epub 2014 Oct 6.

3.

Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916.

Hussain M, Goldman B, Tangen C, Higano CS, Petrylak DP, Wilding G, Akdas AM, Small EJ, Donnelly BJ, Sundram SK, Burch PA, Dipaola RS, Crawford ED.

J Clin Oncol. 2009 May 20;27(15):2450-6. doi: 10.1200/JCO.2008.19.9810. Epub 2009 Apr 20.

4.

Race and survival of men treated for prostate cancer on radiation therapy oncology group phase III randomized trials.

Roach M 3rd, Lu J, Pilepich MV, Asbell SO, Mohiuddin M, Grignon D.

J Urol. 2003 Jan;169(1):245-50.

PMID:
12478146
5.

Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916.

Montgomery RB, Goldman B, Tangen CM, Hussain M, Petrylak DP, Page S, Klein EA, Crawford ED; Southwest Oncology Group.

J Urol. 2007 Nov;178(5):1946-51; discussion 1951. Epub 2007 Sep 17.

PMID:
17868721
6.

Rates of biochemical remission remain higher in black men compared to white men after radical prostatectomy despite similar trends in prostate specific antigen induced stage migration.

Wood HM, Reuther AM, Gilligan TD, Kupelian PA, Modlin CS Jr, Klein EA.

J Urol. 2007 Oct;178(4 Pt 1):1271-6. Epub 2007 Aug 14.

PMID:
17698101
7.

Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group.

Albain KS, Unger JM, Crowley JJ, Coltman CA Jr, Hershman DL.

J Natl Cancer Inst. 2009 Jul 15;101(14):984-92. doi: 10.1093/jnci/djp175. Epub 2009 Jul 7.

8.

Prostate cancer stage shift has eliminated the gap in disease-free survival in black and white American men after radical prostatectomy.

Bianco FJ Jr, Wood DP Jr, Grignon DJ, Sakr WA, Pontes JE, Powell IJ.

J Urol. 2002 Aug;168(2):479-82.

PMID:
12131292
9.

Race and cause specific survival with prostate cancer: influence of clinical stage, Gleason score, age and treatment.

Fowler JE Jr, Bigler SA, Bowman G, Kilambi NK.

J Urol. 2000 Jan;163(1):137-42.

PMID:
10604331
10.

The Risk of Distant Metastases and Cancer Specific Survival in Men with Serum Prostate Specific Antigen Values above 100 ng/ml.

Stattin K, Sandin F, Bratt O, Lambe M.

J Urol. 2015 Dec;194(6):1594-600. doi: 10.1016/j.juro.2015.07.082. Epub 2015 Jul 17.

PMID:
26192253
11.

Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study.

Ahmed HU, Hindley RG, Dickinson L, Freeman A, Kirkham AP, Sahu M, Scott R, Allen C, Van der Meulen J, Emberton M.

Lancet Oncol. 2012 Jun;13(6):622-32. doi: 10.1016/S1470-2045(12)70121-3. Epub 2012 Apr 17.

12.

Impact of race on survival in men with metastatic hormone-refractory prostate cancer.

Halabi S, Small EJ, Vogelzang NJ, Barrier RC Jr, George SL, Gilligan TD.

Urology. 2004 Aug;64(2):212-7.

PMID:
15302462
13.

Early versus deferred androgen suppression in the treatment of advanced prostatic cancer.

Nair B, Wilt T, MacDonald R, Rutks I.

Cochrane Database Syst Rev. 2002;(1):CD003506. Review.

PMID:
11869665
15.

Improvement in prostate cancer survival over time: a 20-year analysis.

Kim MM, Hoffman KE, Levy LB, Frank SJ, Pugh TJ, Choi S, Nguyen QN, McGuire SE, Lee AK, Kuban DA.

Cancer J. 2012 Jan-Feb;18(1):1-8. doi: 10.1097/PPO.0b013e3182467419.

PMID:
22290249
17.

No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year period.

Wu JN, Fish KM, Evans CP, Devere White RW, Dall'Era MA.

Cancer. 2014 Mar 15;120(6):818-23. doi: 10.1002/cncr.28485. Epub 2013 Nov 20.

18.

Association of African-American ethnic background with survival in men with metastatic prostate cancer.

Thompson I, Tangen C, Tolcher A, Crawford E, Eisenberger M, Moinpour C.

J Natl Cancer Inst. 2001 Feb 7;93(3):219-25.

PMID:
11158191
19.

Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer.

Fair WR, Betancourt JE.

Mol Urol. 2000 Fall;4(3):241-8;discussion 249-50.

PMID:
11062380
20.

Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.

Fizazi K, Faivre L, Lesaunier F, Delva R, Gravis G, Rolland F, Priou F, Ferrero JM, Houede N, Mourey L, Theodore C, Krakowski I, Berdah JF, Baciuchka M, Laguerre B, Fl├ęchon A, Ravaud A, Cojean-Zelek I, Oudard S, Labourey JL, Chinet-Charrot P, Legouffe E, Lagrange JL, Linassier C, Deplanque G, Beuzeboc P, Davin JL, Martin AL, Habibian M, Laplanche A, Culine S.

Lancet Oncol. 2015 Jul;16(7):787-94. doi: 10.1016/S1470-2045(15)00011-X. Epub 2015 May 28.

PMID:
26028518

Supplemental Content

Support Center